Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin - AstraZeneca

Drug Profile

Dapagliflozin - AstraZeneca

Alternative Names: Andatang; AZ-dapagliflozin; BMS-512148; BMS-dapagliflozin; BMS/AZ-Dapagliflozin; DAPA; Dapagliflozin-AstraZeneca; Dapagliflozin-propanediol; Farxiga; Forxiga; Oxra

Latest Information Update: 28 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; AstraZeneca KK; Bayer; Bristol-Myers Squibb; Novo Nordisk Foundation; Ono Pharmaceutical; University Medical Center Groningen; Uppsala University
  • Class Antihyperglycaemics; Benzhydryl compounds; Chlorobenzenes; Glucosides; Heart failure therapies; Obesity therapies; Pyrans; Small molecules; Urologics
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Chronic heart failure; Renal failure; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Phase III COVID 2019 infections; Heart failure; Myocardial infarction
  • Phase II Kidney disorders; Obesity; Prediabetic state

Most Recent Events

  • 28 Mar 2022 CTP 321126 (NCT043567420) - No updates, trial not added as Dong-A ST is not associated with development of Dapagliflozin and the drug is launched.
  • 27 Mar 2022 AstraZeneca completes a phase III DELIVER trial for Heart failure in USA, Brazil, Canada, Czech Republic, Hungary, Japan, Mexico, Netherlands, Peru, Romania, Russian Federation, Saudi Arabia, Spain, Taiwan and Vietnam (NCT03619213) (EudraCT2018-000802-46)
  • 22 Feb 2022 First Generic approved in the US for Type-2 diabetes meliitus
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top